Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
Images in Dermatology
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Media and news
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Images
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Study Letters
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
Therapy Letters
View Point
Viewpoint
What’s new in Dermatology
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Search in posts
Search in pages
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
Images in Dermatology
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Media and news
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Images
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Reviewers 2022
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Study Letters
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Review and Meta-Analysis
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
Therapy Letters
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Study Letter
ARTICLE IN PRESS
doi:
10.25259/IJDVL_751_2024

Clinical efficacy and safety of upadacitinib in the treatment of palmoplantar pustulosis: A single-center retrospective study

Department of Dermatology, Tianjin Medical University General Hospital, Tianjin, China
Department of Dermatology, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, China.
Contributed equally to this work.

Corresponding authors: Dr. Suju Luo, Department of Dermatology, Tianjin Medical University General Hospital, 154 Anshan Dao, Tianjin, China. luosuju@tmu.edu.cn

Runping Yang, Department of Dermatology, The Sixth Medical Center of Chinese PLA General Hospital, Beijing, China. yrp809@163.com

Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Zheng Y, Zhang X, Wang H, Yang R, Luo S. Clinical efficacy and safety of upadacitinib in the treatment of palmoplantar pustulosis: A single-center retrospective study. Indian J Dermatol Venereol Leprol. doi: 10.25259/IJDVL_751_2024

Dear Editor,

Palmoplantar pustulosis (PPP) is a rare, chronic, recurrent disease characterised by sterile pustules on the palms and soles. The prevalence of PPP is approximately 0.01– 0.05%. 1 Janus kinase (JAK) inhibitors, including upadacitinib, have been clinically used to treat PPP.2 In this study, we retrospectively analysed the data of 20 PPP patients who received upadacitinib treatment and evaluated its therapeutic efficacy and safety. These patients had previously undergone systemic treatment and/or topical therapy but showed poor response. A chest computed tomography (CT) scan was performed before treatment to detect active tuberculosis. We excluded patients with active tuberculosis, viral infections, severe liver and kidney disease, cardiovascular conditions, malignant diseases, or those who could not comply with treatment recommendations and follow-up requirements. Upadacitinib was administered orally at doses of 15, 30, or 45 mg daily. During the follow-up period (median: 12 weeks; range: 0 to 24 weeks), routine blood tests were performed, and any adverse reactions were recorded. Palmoplantar Pustulosis Area and Severity Index (PPPASI) and Physician Global Assessment (PGA) scores before and after treatment were compared. A 50%, 75%, and 90% improvement in PPPASI was referred to as PPPASI 50, PPPASI 75, and PPPASI 90, respectively. Quantitative data were compared using Student’s t-tests and P < 0.05 was considered significant.

The PPP patients included in this study comprised 6 males and 14 females, with a mean age of 49.50 ± 10.96 years. The patients’ characteristics are detailed in Table 1. Some patients had previously undergone systemic therapies with adalimumab (a monoclonal antibody against tumor necrosis factor α (TNF-α)), ixekizumab (a humanised monoclonal antibody against interleukin-17 (IL-17)), secukinumab (a monoclonal antibody against IL-17), acitretin, and traditional Chinese medicine. The previous treatments were discontinued due to inadequate response. Upadacitinib was used as a rescue treatment for some patients with PPP who showed inadequate response to conventional therapies and biologics. Of the 20 PPP patients, 16 received 15 mg/day of upadacitinib, 3 received 30 mg/day, and 1 received 45 mg/day [Table 2]. After 12 weeks of upadacitinib treatment, erythema, pustules, and desquamation on the palms and soles subsided, as shown in Figures 1a-f and Figure 2a-d. The average PPPASI score decreased significantly from 17.69 ± 11.29 to 1.27 ± 1.41, with the proportions achieving PPPASI 50, PPPASI 75, PPPASI 90, and PPPASI 100 being 100%, 100%, 50%, and 20%, respectively (P < 0.05); [Supplementary Table S1]. The PGA score also significantly improved from 2.70 ± 0.90 to 0.45 ± 0.60 (P < 0.05); [Supplementary Table S1]. No serious adverse events occurred during the treatment period.

Supplementary File 1
Table 1: Basic clinical characteristics of 20 patients with PPP
Case. Gender Age (years)

Disease

duration

Joint pain Nail disease Comorbid conditions Family history PsO AD Previous treatments
1 F 59 1 month Sacroiliac and ankle joints N Hyperlipidemia, urticaria N N N

Tripterygium glycosides 20 mg, tid, for six months caused liver function abnormalities,

Acitretin capsules 20 mg/d, ebastine

2 F 38 3 months Spinaljoint, right sternoclavicular joint N N N N N TCM, Topical medicine (complex formulation of phellodendron, clobetasol, beclomethasone, tazarotene) The effect was not significant.
3 M 60 10 years N Y N Y Y N Adalimumab was administered at 80 mg initially, followed by 40 mg every 2 weeks after one week, with no significant improvement in lesions after 5 treatments AD-like rashes appeared on the limbs, with severe itching.
4 F 32 6 years N N N N Y N Ixekizumab was administered at 160 mg at week 0, followed by 80 mg at weeks 2, 4, 6, 8, 10, and 12, and then 80 mg every 4 weeks for a total of 2 years, after which the disease relapsed.
5 F 40 1 year N Y N N N N

TCM

The effect was not significant.

6 M 37 2 months Sterno-clavicular joint Y Hyperglycemia N N N

TPSO

The effect was not significant.

7 F 55 4 month N Y N N N N

TPSO, Terbinafine, Terbinafine cream

The effect was not significant.

8 M 44 8 months N N N Y Y N

TPSO

The effect was not significant.

9 M 54 2 months N Y Diabetes N N Y

TCM, TPSO

The effect was not significant.

10 M 45 3 months N N N N N N

Clobetasol/triclosan cream

The effect was not significant.

11 F 48 10 years Sternoclavicular, bilateral shoulder, bilateral hands distal interphalangeal joints Y N N Y N After seven treatments with secukinumab, there was no significant improvement. Treatment was switched to adalimumab, and after two treatments, the rashes on the trunk and limbs, as well as joint pain, were alleviated compared to before. However, new pustules still appeared on the hands and feet. Methotrexate was administered orally at 10 mg per week, resulting in the gradual resolution of the pustules on the hands and feet, with no significant joint pain. After 24 weeks of treatment, AD-like rashes appeared on the lower legs, with severe itching affecting daily life.
12 F 58 9 months Left knee, cervical spine Y Uveitis N N Y

TPSO

The effect was not significant.

13 F 55 2 months Sternoclavicular, bilateral knees, hips, shoulders, elbows, bilateral hands interphalangeal joints N Rhinitis, pharyngitis N N N Adalimumab was administered at 80 mg initially, followed by 40 mg every 2 weeks after one week, with no significant improvement in lesions after 12 weeks AD-like rashes appeared on the limbs, with severe itching, Leflunomide 10 mg qd for 3 months, Clobetasol/triclosan cream, Calcipotriol ointment.
14 F 33 10 years N N Hypothyroidism N N Y

TCM, TPSO

The effect was not significant.

15 M 44 2 years Sterno-clavicular, hip, left foot first metatarsophalangeal joint Y N Y Y N Adalimumab, Thalidomide
16 F 46 7 years N Y Hyperlipidemia, gallstones N N N

TCM, TPSO

The effect was not significant.

17 F 59 7 months Sternum Y Hypertension, diabetes, angina N N N Tripterygium glycosides, Sulfasalazine, Clobetasol/triclosan cream The effect was not significant.
18 F 53 3 weeks Shoulder N Ulcerative colitis N N N Untreated
19 F 77 2 months Right ankle Y Hyperglycemia, hyperlipidemia N N N N
20 F 57 3 months N Y Hypertension, hypothyroidism N N N Acitretin 20 mg orally for 3 months resulted in elevated blood lipids.

F: female; M: male; PsO: Psoriasis; AD: Atopic Dermatitis; N: none; Y: yes; TCM: Traditional Chinese medicine; TPSO: Topical potent steroid ointment.

Table 2: Upadacitinib treatment along with concomitant systemic and topical therapies details in 20 PPP patients
Case. Upadacitinib Dose Systemic Treatment Concomitance Topical Treatment Concomitance PGA Before Treatment PGA at 12 Weeks PPPASI Before Treatment PPPASI at 12 Weeks Adverse Events
1 15 mg Ebastine N 2 0 10.8 0 N
2 15 mg N Calcipotriol, Clobetasol/triclosan 2 0 6.2 0 N
3 30 mg N N 5 1 48.6 3.8 N
4 15 mg N N 2 0 6.4 0 N
5 15 mg N N 2 0 5.4 0 N
6 15 mg Ebastine Calcipotriol, Clobetasol/triclosan 4 1 22.2 1.1 N
7 15 mg N Triamcinolone acetonide/urea cream 2 0 11.2 0 N
8 15 mg N N 3 0 11 0 N
9 15 mg N N 2 0 10.8 1.2 N
10 15 mg N N 2 0 8.8 1.1 N
11 30 mg Ebastine N 2 1 12 2 N
12 15 mg N N 2 0 6.2 0 N
13 30 mg N Calcipotriol, Clobetasol/triclosan 3 1 24 2.2 N
14 15 mg N N 2 0 8.4 1.2 N
15 15 mg N N 4 2 24 2.6 N
16 15 mg N N 4 2 32 5.2 N
17 15 mg N N 3 0 25.8 1.2 N
18 45 mg N N 2 0 21 0 Transient increase in blood pressure
19 15 mg N N 3 0 27 1.2 N
20 15 mg N Calcipotriol, Triamcinolone acetonide 3 1 32 2.6 N

N: none; PPPASI: Palmoplantar Pustulosis Area and Severity Index; PGA: Physician Global Assessment

The PPPASI improvement rate was calculated as follows: PPPASI Score = Right palm [(Erythema + Pustules + Desquamation) × Area ×0.2]+Left palm [(Erythema + Pustules + Desquamation) × Area × 0.2] + Right sole [(Erythema + Pustules + Desquamation) × Area × 0.3] + Left sole [(Erythema + Pustules + Desquamation) × Area × 0.3]. Erythema, pustules, and desquamation scores: 0 = absent, 1 = mild, 2 = moderate, 3 = severe, 4 = very severe.

A 59-years old woman with palmo-plantar lesions at baseline (a-c) and after 12-weeks of upadacitinib treatment (d-f).
Figure 1:
A 59-years old woman with palmo-plantar lesions at baseline (a-c) and after 12-weeks of upadacitinib treatment (d-f).
A 38-year-old women in 8 months postpartum with PPP, before Upadacitinib treatment (a-b) and after 12 weeks of updacitinib treatment (c-d).
Figure 2:
A 38-year-old women in 8 months postpartum with PPP, before Upadacitinib treatment (a-b) and after 12 weeks of updacitinib treatment (c-d).

Upadacitinib is currently approved for various pathological conditions, including atopic dermatitis (AD), psoriatic arthritis (PsA), rheumatoid arthritis (RA), and ulcerative colitis (UC).3 It can be utilised to treat AD-like rashes that occur during biological treatment for PsA. In this study, two patients with PPP and PsA developed AD-like rashes following injections of adalimumab and secukinumab. They then switched to upadacitinib treatment, which resolved AD-like rashes. It has been documented that 5–20% of patients receiving TNF-α antagonists for various inflammatory diseases develop AD-like rashes.4 Disruption of the balance between pro- and anti-inflammatory cytokines may account for the development of AD-like rashes after treatment with TNF-α antagonists. Upadacitinib can also be used to treat PPP manifestations that occur following the treatment of immune diseases such as UC and RA. One of our patients, who had a 10-year history of UC, developed PPP manifestations after treatment with vedolizumab (a monoclonal antibody against α4β7 integrin) and infliximab (a monoclonal antibody against TNF-α). According to the instructions for use, the patient received oral upadacitinib (45 mg/day), resulting in a marked improvement in joint pain and rashes. During the treatment period, no adverse effects were observed except for a transient increase in blood pressure. It has been reported that oral administration of upadacitinib (15 mg/day) effectively mitigates skin lesions in two PPP patients with PsA who exhibited a poor response after the IL-17 inhibitor treatment.5 Similar findings were observed in our cohort of 10 PPP patients with PsA, confirming the therapeutic value of upadacitinib for PPP patients.

A retrospective study design, a small sample size, and a short follow-up period are the main limitations of this study. Potential adverse events associated with the use of JAK inhibitors include cardiovascular diseases, thrombosis, and infections.6 Therefore, during the treatment with upadacitinib, routine blood and coagulation function tests are necessary.

In conclusion, upadacitinib is effective in relieving the symptoms of PPP. However, the long-term safety of upadacitinib still requires further investigation.

Ethical approval

The research/study was approved by the Institutional Review Board at Tianjin Medical University General Hospital, number IRB2024-YX-006-01, dated 2023-01.

Declaration of patient consent

The authors certify that they have obtained all appropriate patient consent.

Financial support and sponsorship

National Natural Science Foundation of China, Grant/Award Number: 81773319; Tianjin Key Medical Discipline (Specialty) Construction Projectuff08No:TJYXZDXK-057Buff09

Conflicts of interest

There are no conflicts of interest.

Use of artificial intelligence (AI)-assisted technology for manuscript preparation

The authors confirm that there was no use of artificial intelligence (AI)-assisted technology for assisting in the writing or editing of the manuscript and no images were manipulated using AI.

References

  1. , . Recent advances in palmoplantar pustulosis. Fac Rev. 2021;10:62.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  2. , , . Palmoplantar pustulosis successfully treated with upadacitinib: Report of three cases. Australas J Dermatol. 2023;64:568-70.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , , , , et al. The JAK-STAT pathway at 30: Much learned, much more to do. Cell. 2022;185:3857-76.
    [CrossRef] [PubMed] [PubMed Central] [Google Scholar]
  4. , , , , , , et al. Eczema as an adverse effect of anti-TNFα therapy in psoriasis and other Th1-mediated diseases: A review. Dermatol Treat. 2017;28:237-241.
    [Google Scholar]
  5. , , , . Palmoplantar pustulosis with psoriatic arthritis ineffective to interleukin-17 inhibitors: two patients successfully treated with upadacitinib. J Dermatology Treat. 2023;34:2280508.
    [CrossRef] [Google Scholar]
  6. , , , , , , et al. English version of Japanese guidance for the use of oral Janus kinase inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis. J Dermatol. 2023;50:e138-e150.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views
2,563

PDF downloads
55
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections